08/05/22 7:30 AMOTC : ACHFF clinical trialArch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical TrialsArch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic AdvisorRHEA-AIneutral
02/14/22 7:30 AMOTC : ACHFF covid-19Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)Arch Biopartners Inc. (“ArchRHEA-AIneutral
02/03/22 7:30 AMOTC : ACHFF Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney InjuryArch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal ScienceRHEA-AIneutral
01/04/22 7:25 AMOTC : ACHFF covid-19Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)Arch Biopartners Inc. (“ArchRHEA-AIneutral
12/01/21 7:35 AMOTC : ACHFF covid-19Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) TrialLSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type. LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, aRHEA-AIneutral
08/05/21 6:30 AMOTC : ACHFF Arch Biopartners Provides Update on Phase II Trial for LSALT PeptideArch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results ofRHEA-AIneutral
07/14/21 7:00 AMOTC : ACHFF Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic DiseaseArch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Arch scientists have been awarded aRHEA-AIvery positive
06/10/21 7:20 AMOTC : ACHFF Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ InflammationArch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patentRHEA-AIneutral
05/04/21 7:00 AMOTC : ACHFF covid-19Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has completed enrollment for its Phase IIRHEA-AIneutral
04/15/21 7:00 AMOTC : ACHFF Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney InjuryArch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation Novel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists that prevent leukocyte adhesion to endothelial cells reducing inflammation and subsequent organRHEA-AIneutral